Cargando…
Clinical and radiologic outcomes in two patients with multiple sclerosis treated with tocilizumab for COVID-19
BACKGROUND: Tocilizumab is an interleukin-6 receptor antagonist used to treat COVID-19. A previous case report described development of multiple sclerosis (MS) after treatment with tocilizumab for rheumatoid arthritis, leading to an FDA warning label. We sought to identify patients with multiple scl...
Autores principales: | Holroyd, Kathryn B., Conway, Sarah E., Bhattacharyya, Shamik, Galetta, Kristin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier B.V.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750953/ http://dx.doi.org/10.1016/j.nerep.2022.100061 |
Ejemplares similares
-
COVID-19 severity is associated with worsened neurological outcomes in multiple sclerosis and related disorders
por: Conway, Sarah E., et al.
Publicado: (2022) -
Humoral response to COVID-19 vaccination in MS patients on disease modifying therapy: Immune profiles and clinical outcomes
por: Holroyd, Kathryn B., et al.
Publicado: (2022) -
Reactivation of SARS-CoV-2 after Rituximab in a Patient with Multiple Sclerosis
por: Bose, Gauruv, et al.
Publicado: (2021) -
The clinical-radiological paradox in multiple sclerosis: myth or truth?
por: Hartmann, Ana, et al.
Publicado: (2023) -
Serum neurofilament levels and patient‐reported outcomes in multiple sclerosis
por: Galetta, Kristin, et al.
Publicado: (2021)